Ontology highlight
ABSTRACT: Background
Lucitanib is an oral, potent, selective inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1‒3, fibroblast growth factor receptors 1‒3, and platelet-derived growth factor receptors alpha/beta.Objective
We aimed to develop a population pharmacokinetics (PopPK) model for lucitanib in patients with advanced cancers.Methods
PopPK analyses were based on intensive and sparse oral pharmacokinetic data from 5 phase 1/2 clinical studies of lucitanib in a total of 403 patients with advanced cancers. Lucitanib was administered at 5‒30 mg daily doses as 1 of 2 immediate-release oral formulations: a film-coated tablet or a hard gelatin capsule.Results
Lucitanib pharmacokinetics were best described by a 2-compartment model
SUBMITTER: Liao M
PROVIDER: S-EPMC9399017 | biostudies-literature | 2022 Sep
REPOSITORIES: biostudies-literature